Anti-PD-1? Well, no, says Medivation as a partial hold forces a halt to ‘pivotal’ cancer study

John Carroll

When bought out the rights to CureTech's pidilizumab, it trumpeted its entry into checkpoint inhibition with a drug that aimed right at PD-1, unleashing a T cell attack on . Except that Medivation recently concluded that the drug doesn't work that way after all–and now the FDA has red-flagged a of the drug, halting the trial through a clinical while Medivation takes another stab at explaining the mechanism of action.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS